Signaturefd LLC Boosts Holdings in Merck & Co., Inc. $MRK

Signaturefd LLC raised its position in Merck & Co., Inc. (NYSE:MRK) by 9.9% in the 4th quarter, Holdings Channel.com reports. The fund owned 51,409 shares of the company’s stock after acquiring an additional 4,644 shares during the quarter. Signaturefd LLC’s holdings in Merck & Co., Inc. were worth $5,411,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Darwin Wealth Management LLC lifted its holdings in shares of Merck & Co., Inc. by 237.4% during the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after purchasing an additional 216 shares during the last quarter. Barnes Dennig Private Wealth Management LLC boosted its position in shares of Merck & Co., Inc. by 302.3% in the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after purchasing an additional 266 shares in the last quarter. Evolution Wealth Management Inc. purchased a new position in Merck & Co., Inc. during the 2nd quarter worth $31,000. United Financial Planning Group LLC purchased a new position in Merck & Co., Inc. during the 3rd quarter worth $31,000. Finally, Wealth Watch Advisors INC acquired a new position in Merck & Co., Inc. during the 3rd quarter valued at about $34,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Stock Down 0.2%

NYSE:MRK opened at $120.62 on Friday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. The company’s fifty day moving average price is $117.72 and its 200-day moving average price is $103.23. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The firm has a market capitalization of $298.21 billion, a P/E ratio of 16.57, a PEG ratio of 2.44 and a beta of 0.26.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. During the same period in the previous year, the firm posted $1.72 earnings per share. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, March 16th. Merck & Co., Inc.’s payout ratio is 46.70%.

Analysts Set New Price Targets

Several brokerages have weighed in on MRK. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. Guggenheim increased their price objective on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Bank of America lifted their target price on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Finally, UBS Group boosted their target price on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $127.13.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: EU approval expands KEYTRUDA use to PD?L1 positive, platinum?resistant ovarian cancer — opens a new commercial indication in Europe for an established franchise, which can drive incremental revenue and utilization in a high?unmet?need setting. Merck Broadens Cancer And Eye Disease Pipeline As Investors Weigh Future Growth
• Positive Sentiment: Merck initiated a pivotal Phase 2b/3 trial of MK?8748 (Tiespectus) for wet AMD — a promising ophthalmology program that, if successful, adds a non?oncology growth vector and diversifies long?term revenue streams. Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus)
• Positive Sentiment: Positive Phase 3 CORALreef results for oral PCSK9 inhibitor (enlicitide decanoate) — if approved, an oral PCSK9 could be a major commercial opportunity in cardiovascular prevention and complement existing lipid therapies. Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9
• Positive Sentiment: Detailed Phase 2 CADENCE data for WINREVAIR released — adds evidence to a respiratory program that management can highlight to investors as part of a broader R&D pipeline story. Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study
• Neutral Sentiment: Merck KGaA acquisition of JSR chromatography business noted in the press — this concerns Merck KGaA (a different company) and is unlikely to meaningfully affect Merck & Co.’s (MRK) near?term fundamentals. Merck KGaA acquires JSR chromatography
• Negative Sentiment: New proposal from former President Trump to impose up to 100% tariffs on imported medicines (with carve?outs) increases regulatory and pricing uncertainty for the sector; even with exemptions, the proposal raises near?term headline risk and could pressure sentiment toward large pharma names like MRK until policy clarity emerges. Trump Unveils Up to 100% Tariffs on Imported Medicines With Key Exemptions
• Negative Sentiment: Sector policy debate over drug?pricing deals continues (Lilly warns against locking pricing deals into law) — ongoing political scrutiny increases the chance of policy actions that could cap pricing or change reimbursement, a headwind for long?term margin visibility. Lilly Pushes Back on Making Drug Price Deals Permanent

Insiders Place Their Bets

In other news, EVP Richard R. Deluca sold 37,685 shares of the company’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $120.92, for a total value of $4,556,870.20. Following the sale, the executive vice president owned 160,174 shares in the company, valued at $19,368,240.08. This represents a 19.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Caroline Litchfield sold 41,997 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $119.61, for a total value of $5,023,261.17. Following the sale, the chief financial officer directly owned 90,192 shares in the company, valued at approximately $10,787,865.12. This trade represents a 31.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 320,176 shares of company stock worth $38,281,735. 0.13% of the stock is currently owned by company insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.